Back to Agendas
[V4-S4] Future Perspective of Personalized Medicines in Oncology Disease Area - Can You Imagine How NGS Technology is Being Expanded in Japan? -
Session Chair(s)
Tomoko Hirohashi, PhD
Director, Clinical Research Oncology, Pfizer Japan Inc., Japan
Scientific technology has significantly improved, and understanding of molecular mechanisms of cancer has increased considerably. With these changes, the technology for biomarker investigations or diagnostic method has been also improved. The representative example is next generation sequencing (NGS) technology. However there are lots of challenges to be cleared for its clinical and practical use whereas next generation sequencing will have a lot of potential. In this session, we will discuss the options to use this new technology for cancer patients.
Speaker(s)
Tomoko Hirohashi, PhD
Director, Clinical Research Oncology, Pfizer Japan Inc., Japan
Future Perspective of Personalized Medicines in Oncology Disease Area - Can You Imagine How NGS Technology is Being Expanded in Japan?
Takayuki Yoshino, MD, PhD
Department of Gaestrointestinal Oncology, National Cancer Center Hospital East, Japan
Activities on Academia of Clinical Sequencing with NGS from the Experience of Clinical Development of Multiplex Diagnostic Kit
Mariko Yamaguchi
Senior Manager, RA/QA and Clinical Affairs,, QIAGEN K.K., Japan
Expectation and Challenge of Implementation for Multiple Marker and NGS - View Points of Both Drug and Diagnostic Companies
Manabu Muto, MD, PhD
Professor, Department of Therapeutic Oncology, Graduate School of Medicine, Graduate School of Medicine, Kyoto University, Japan
Implementation of Clinical Sequencing in Kyoto University
Have an account?